RE:RE:RE:Press Release I don't think it's being marked up. I think after tax loss selling season we are back to a more "normal" share price trading although it is still severely undervalued when the two analysts have share price targets (where they think it should be valued and trading at right now) which are double the current share price.
As more and more people realize the significance of having more Business Development (BD) deal(s) (aka licensing deals) transacted in the next few months, no plans or need to do any dilutive financing, and the "pot of gold at the end of the rainbow" opportunity that could happen now that we are open to partnering for our drug development program xB3-001 (for brain cancer), the higher the share price is going to rise.
Once we are above .47 on some volume it will attract even more eyes.